VosoritideMeSH Supplementary Concept

https://www.has-sante.fr/jcms/p_3598534/fr/voxzogo-vosoritide-achondroplasie-chez-les-patients-ages-de-4-mois-a-moins-de-5-ans
2025
false
false
false
France
infant
child
treatment outcome
insurance, health, reimbursement
injections, subcutaneous
vosoritide
evaluation of the transparency committee
vosoritide
achondroplasia

---
https://ansm.sante.fr/informations-de-securite/voxzogo-vosoritide-modification-de-la-seringue-et-de-laiguille-conduisant-a-une-administration-exprimee-en-unites-u-au-lieu-de-ml
2023
false
false
false
France
French
vosoritide
guidelines for drug use
Syringe markings confusion
risk

---
https://www.has-sante.fr/jcms/p_3385532/fr/voxzogo-0-4-0-56-1-2-mg-vosoritide-achondroplasie
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
vosoritide
child
adolescent
evaluation of the transparency committee
achondroplasia
vosoritide

---
https://www.has-sante.fr/jcms/p_3313571/fr/voxzogo-vosoritide
2022
false
false
false
France
insurance, health, reimbursement
treatment outcome
vosoritide
achondroplasia
child, preschool
injections, subcutaneous
achondroplasia
evaluation of the transparency committee
vosoritide
Voxzogo

---
https://www.has-sante.fr/jcms/p_3385532/en/voxzogo-0-4-0-56-1-2-mg-vosoritide-achondroplasie
2022
false
false
false
France
treatment outcome
vosoritide
vosoritide
child
adolescent
achondroplasia
injections, subcutaneous
evaluation of the transparency committee

---
https://www.ema.europa.eu/en/medicines/human/EPAR/voxzogo
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
vosoritide
vosoritide
vosoritide
orphan drug production
achondroplasia
child
injections, subcutaneous
genetic testing
achondroplasia
FGFR3 Gene
product surveillance, postmarketing
continuity of patient care

---
https://ansm.sante.fr/tableau-atu-rtu/voxzogo-0-4-mg-poudre-et-solvant-pour-solution-injectable-voxzogo-0-56-mg-poudre-et-solvant-pour-solution-injectable-voxzogo-1-2-mg-poudre-et-solvant-pour-solution-injectable
2021
false
false
false
France
French
guidelines for drug use
vosoritide
vosoritide
child
achondroplasia
package leaflet
vosoritide
natriuretic peptide, C-type
natriuretic peptide, C-type
natriuretic peptide, C-type

---
https://www.has-sante.fr/jcms/p_3304519/fr/voxzogo-0-4-0-56-1-2-mg-vosoritide
https://has-sante.fr/jcms/p_3304532/fr/decision-n-2021-0291/dp/sem-du-13-decembre-2021-de-la-presidente-de-la-haute-autorite-de-sante-prise-au-nom-du-college-portant-autorisation-d-acces-precoce-de-la-specialite-voxzogo
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
achondroplasia
child
rare diseases
continuity of patient care
guidelines for drug use
injections
orphan drug production
vosoritide
evaluation of the transparency committee
vosoritide

---